Boston Scientific Shares Surge 9% Following Q1 Earnings Beat

Shares of medical device developer Boston Scientific (NYSE: BSX) surged nearly 9% on Wednesday, closing at $64.87. The rally was triggered by first-quarter financial results that surpassed Wall Street estimates, providing a reprieve for investors after a period of sustained decline. For the first quarter, the company reported a 9% increase in sales and a 6% rise in adjusted earnings per share (EPS). Despite these beats, management lowered its full-year 2026 sales growth guidance, adjusting the midpoint from 10.5% down to 7.25%. The positive market reaction is particularly notable given the stock's recent performance. Boston Scientific shares have fallen 37% over the last six months, pressured by disappointing February earnings and underwhelming clinical trial data regarding its Watchman heart implant released three weeks ago. Trading activity was intense, with volume reaching 40.4 million shares, representing a 138% increase over the three-month average of 17 million shares. The company is currently trading at 19 times forward earnings, a valuation that may have made the Q1 beat more attractive to value-oriented investors. While industry peers also saw gains, the movement was significantly more muted. Medtronic closed up 1.49% at $83.22, and Stryker finished up 0.63% at $329.35, highlighting that the primary catalyst for the day's volatility was specific to Boston Scientific's internal reset of growth expectations.